We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Non-Invasive Diagnostic Test Improves Detection of Oral Cancer

By LabMedica International staff writers
Posted on 04 Apr 2023

Oral squamous cell carcinoma (OSCC) is a highly prevalent type of cancer that affects the lining of the mouth and throat, and is strongly associated with lifestyle factors such as smoking, alcohol use, or poor oral hygiene. More...

Symptoms of OSCC include persistent mouth sores, difficulty swallowing, and changes in speech. The disease can be successfully treated if detected early, but prognosis is poor if diagnosed at a late stage. Oral epithelial dysplasia (OED) is a precursor condition to OSCC, in which the lining of the mouth shows abnormal changes in shape, size, and arrangement due to lifestyle factors such as smoking or alcohol use. OED can progress to oral cancer if not detected and treated early. With more than three hundred thousand people worldwide being diagnosed with oral cancer, the mortality rate of around 50% is alarming, indicating a lack of effective tools for early detection.

Now, scientists at the University of Surrey (Guildford, UK) have developed PANDORA, a proof-of-concept test that demonstrated over 92% accuracy in identifying patients with OSCC and over 80% accuracy in detecting pre-cancer or OED. The study involved taking cell samples from a test group of 40 people with OSCC and OED, as well as 79 people without cancer, including those with other benign lesions. The DEPtech 3DEP analyzer, with a unique set-up protocol, was utilized to measure and analyze the patient's cells. Since samples can be obtained at a dentist's office and sent for analysis via post, the test can be used in primary care to identify patients requiring specialist care.

“Over three hundred thousand people are diagnosed with oral cancer worldwide – a disease with an alarming mortality rate of around 50%,” said Dr. Fatima Labeed, co-author of the study and Senior Lecturer in Human Biology from the University of Surrey. “This suggests that the scientific community doesn't have the tools available to identify oral cancer early enough, and we hope that PANDORA paves the way for more effective clinical diagnostic tools for this terrible disease.”

Related Links:
University of Surrey


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.